Price Alert

Immunome Inc. (IMNM)

NASDAQ: IMNM · Real-Time Price · USD

12.38

0.91 (7.93%)

At close: Oct 03, 2025, 3:59 PM

12.57

1.53%

After-hours: Oct 03, 2025, 07:08 PM EDT

Immunome Statistics

Share Statistics

Immunome has 87.05M shares outstanding. The number of shares has increased by 39.46% in one year.

Shares Outstanding	87.05M
Shares Change (YoY)	39.46%
Shares Change (QoQ)	0.04%
Owned by Institutions (%)	91.29%
Shares Floating	70.79M
Failed to Deliver (FTD) Shares	896
FTD / Avg. Volume	0.08%

Short Selling Information

The latest short interest is 14.97M, so 17.2% of the outstanding shares have been sold short.

Short Interest	14.97M
Short % of Shares Out	17.2%
Short % of Float	17.97%
Short Ratio (days to cover)	10.12

Valuation Ratios

The PE ratio is -2.13 and the forward PE ratio is -4.94. Immunome's PEG ratio is 0.3.

PE Ratio	-2.13
Forward PE	-4.94
PS Ratio	68.88
Forward PS	77.9
PB Ratio	3.44
P/FCF Ratio	-5.28
PEG Ratio	0.3

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Immunome.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.03.

Current Ratio	4.08
Quick Ratio	4.08
Debt / Equity	0.03
Debt / EBITDA	-0.03
Debt / FCF	-0.04
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$69.02K
Profits Per Employee	$-2.24M
Employee Count	131
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by -6% in the last 52 weeks. The beta is 1.95, so Immunome's price volatility has been higher than the market average.

Beta	1.95
52-Week Price Change	-6%
50-Day Moving Average	10.2
200-Day Moving Average	9.39
Relative Strength Index (RSI)	63.96
Average Volume (20 Days)	1,134,028

Income Statement

In the last 12 months, Immunome had revenue of 9.04M and earned -292.96M in profits. Earnings per share was -5.

Revenue	9.04M
Gross Profit	9.04M
Operating Income	-305.8M
Net Income	-292.96M
EBITDA	-151.35M
EBIT	-153.46M
Earnings Per Share (EPS)	-5

Full Income Statement

Balance Sheet

The company has 143.35M in cash and 4.83M in debt, giving a net cash position of 138.52M.

Cash & Cash Equivalents	143.35M
Total Debt	4.83M
Net Cash	138.52M
Retained Earnings	-515.77M
Total Assets	296.29M
Working Capital	254.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -110.79M and capital expenditures -7.17M, giving a free cash flow of -117.97M.

Operating Cash Flow	-110.79M
Capital Expenditures	-7.17M
Free Cash Flow	-117.97M
FCF Per Share	-2.01

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -3382.37% and -3240.38%.

Gross Margin	100%
Operating Margin	-3382.37%
Pretax Margin	-3240.38%
Profit Margin	-3240.38%
EBITDA Margin	-1674.08%
EBIT Margin	-3382.37%
FCF Margin	-1304.8%

Dividends & Yields

IMNM does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for IMNM is $24, which is 93.9% higher than the current price. The consensus rating is "Buy".

Price Target	$24
Price Target Difference	93.9%
Analyst Consensus	Buy
Analyst Count	9

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	15.74
Piotroski F-Score	2